Details of the Drug Inactive Ingredient (DIG)

General Information of DIG (ID: E0H2RX)
DIG Name
Glyceryl monostearate
Synonyms    Click to Show/Hide the Synonyms of This DIG
Glyceryl monostearate; Monostearin; 123-94-4; GLYCEROL MONOSTEARATE; 31566-31-1; Glyceryl stearate; 1-Stearoyl-rac-glycerol; Tegin; 1-MONOSTEARIN; Octadecanoic acid, 2,3-dihydroxypropyl ester; 1-Glyceryl stearate; Stearic acid 1-monoglyceride; Stearin, 1-mono-; 1-Monostearoylglycerol; Sandin EU; Glycerin 1-monostearate; Glycerol 1-monostearate; Aldo MSD; Aldo MSLG; Glycerin 1-stearate; Glycerol 1-stearate; Stearoylglycerol; Arlacel 165; Tegin 55G; alpha-Monostearin; Emerest 2407; Aldo 33; Aldo 75; 2,3-dihydroxypropyl octadecanoate; Glyceryl 1-monostearate; Glycerin monostearate; 3-Stearoyloxy-1,2-propanediol; Glycerol alpha-monostearate; .alpha.-Monostearin; Monoglyceryl stearate; Tegin 515; Monostearate (glyceride); Glyceryl monooctadecanoate; 1-octadecanoyl-rac-glycerol; NSC 3875; Stearic acid, monoester with glycerol; 2,3-Dihydroxypropyl stearate; NSC3875; MONOSTEARIN (L); rac-1-monostearoylglycerol; Glycerol .alpha.-monostearate; MG(18:0/0:0/0:0)[rac]; CHEBI:75555; Stearic acid .alpha.-monoglyceride; MFCD00036186; Octadecanoic acid, monoester with 1,2,3-propanetriol; NCGC00164529-01; DSSTox_CID_9160; DSSTox_RID_78691; DSSTox_GSID_29160; Cefatin; Dermagine; Monelgin; Sedetine; Admul; Orbon; Citomulgan M; Drewmulse V; Cerasynt S; Drewmulse TP; Cerasynt SD; Cerasynt SE; Cerasynt WM; Cyclochem GMS; Drumulse AA; Protachem GMS; Witconol MS; Witconol MST; Unimate GMS; Ogeen M; Stearin, mono-; Emcol CA; Emcol MSK; Hodag GMS; Ogeen GRB; Ogeen MAV; Aldo HMS; Aldo MS; Celinhol - A; (+/-)-2,3-Dihydroxypropyl octadecanoate; 1-Glyceryl stearate; 1-Monooctadecanoylglycerol; 1-Monostearin; CAS-123-94-4; Armostat 801; Myvaplex 600; Stearic monoglyceride; Kessco 40; Abracol S.L.G.; Advawax 140; Arlacel 161; Arlacel 169; FEMA No. 2527; Imwitor 191; Imwitor 900K; Atmul 67; Atmul 84; Starfol GMS 450; Starfol GMS 600; Starfol GMS 900; Stearic acid alpha-monoglyceride; Cerasynt 1000-D; Emerest 2401; Aldo-28; Aldo-72; Atmos 150; Atmul 124; Estol 603; Glycerol stearate, pure; Grocor 5500; Grocor 6000; Ogeen 515; Tegin 503; Lipo GMS 410; Lipo GMS 450; Lipo GMS 600; EINECS 204-664-4; EINECS 245-121-1; USAF KE-7; EMUL P.7; TEGIN 90; (R)-2,3-Dihydroxypropyl stearate; 22610-63-5; Glyceryl monostearate [JAN:NF]; Tegin (Related); 1-MONOSTEAROYL-rac-GLYCEROL; (1)-2,3-Dihydroxypropyl stearate; 1,2,3-Propanetriol, homopolymer, isooctadecanoate; 1,2,3-Propanetriol, homopolymer, monooctadecanoate; EINECS 250-705-4; 1,2,3-Propanetriol monooctadecanoate; Eastman 600; 1-O-stearoylglycerol; 1-octadecanoylglycerol; Monostearin (Related); Glycerol Mono Stearate; rac-octadecanoylglycerol; Triglyceryl monostearate; Polyglyceryl-3 stearate; glycerol 1-octadecanoate; Glyceryl 1-octadecanoate; rac-glyceryl monostearate; AI3-00966; Tegin 515 (Related); Glycerol .alpha.-sterate; (+-)-1-stearoylglycerol; Glyceryl monopalmitostearate; EC 250-705-4; SCHEMBL4488; (+-)-glyceryl monostearate; Geleol mono and diglycerides; Glyceryl stearate (Related); DSSTox_RID_78757; DSSTox_GSID_29304; Glycerol monostearate (GMS); (+-)-1-monostearoylglycerol; (+-)-1-octadecanoylglycerol; 37349-34-1; 83138-62-9; Stearin, 1-mono- (8CI); Glycerol monostearate, purified; CHEMBL255696; Glyceryl monostearate (Related); 2,3-Dihydroxypropyl stearate #; DTXSID7029160; CHEBI:75557; Glyceryl monostearate (JP17/NF); 1-Stearoyl-rac-glycerol, >=99%; NSC-3875; EINECS 238-880-5; Tox21_112160; Tox21_202573; Tox21_301104; ANW-27153; LMGL01010003; rac-2,3-dihydroxypropyl octadecanoate; AKOS015901589; Tox21_112160_1; DB11250; MCULE-2198239945; (+-)-2,3-dihydroxypropyl octadecanoate; NCGC00164529-02; NCGC00164529-03; NCGC00164529-04; NCGC00255004-01; NCGC00260122-01; Octadecanoic acid,3-dihydroxypropyl ester; 1,2,3-Propanetriol 1-octadecanoyl ester; 85666-92-8; AK175522; Octadecanoic acid, monoester with 3,3'-((2-hydroxy-1,3-propanediyl)bis(oxy))bis(1,2-propanediol-; P566; CAS-11099-07-3; FT-0626740; FT-0626748; FT-0674656; G0085; Octadecanoic acid, 2.3-dihydroxypropyl ester; ST51037333; 1379-EP2270002A1; 1379-EP2270006A1; 1379-EP2270011A1; 1379-EP2277861A1; 1379-EP2277865A1; 1379-EP2281823A2; 1379-EP2289892A1; 1379-EP2292234A1; 1379-EP2292593A2; 1379-EP2295406A1; 1379-EP2295409A1; 1379-EP2295424A1; 1379-EP2295426A1; 1379-EP2295427A1; 1379-EP2298742A1; 1379-EP2298747A1; 1379-EP2298766A1; 1379-EP2298772A1; 1379-EP2301536A1; 1379-EP2301538A1; 1379-EP2301922A1; 1379-EP2301931A1; 1379-EP2305641A1; 1379-EP2305648A1; 1379-EP2308492A1; 1379-EP2308839A1; 1379-EP2308869A1; 1379-EP2311455A1; 1379-EP2311821A1; 1379-EP2311829A1; 1379-EP2314590A1; 1379-EP2316452A1; 1379-EP2374792A1; 3889-EP2295430A2; 3889-EP2295431A2; 3889-EP2305668A1; 3889-EP2374787A1; D01947; SR-01000944874; Q-201168; Q5572563; SR-01000944874-1; W-110285; Octadecanoic acid, monoester with tri-1,2,3-propanetriol diether; 342394-34-7
DIG Function
Emollient; Emulsifying agent; Emulsion stabilizing agent; Solubilizing agent; Surfactant; Viscosity-controlling agent
PubChem CID
24699
Formula
C21H42O4
Canonical SMILES
CCCCCCCCCCCCCCCCCC(=O)OCC(CO)O
InChI
1S/C21H42O4/c1-2-3-4-5-6-7-8-9-10-11-12-13-14-15-16-17-21(24)25-19-20(23)18-22/h20,22-23H,2-19H2,1H3
InChIKey
VBICKXHEKHSIBG-UHFFFAOYSA-N
   Click to Show/Hide the Molecular Data (Structure/Property) of This DIG
Structure
<iframe style="width: 300px; height: 300px;" frameborder="0" src="https://embed.molview.org/v1/?mode=balls&cid=24699"></iframe>
3D MOL is not available 2D MOL
Physicochemical Properties Molecular Weight 358.6 Topological Polar Surface Area 66.8
XlogP 7.4 Complexity 281
Heavy Atom Count 25 Rotatable Bond Count 20
Hydrogen Bond Donor Count 2 Hydrogen Bond Acceptor Count 4
Full List of Active Pharmaceutical Ingredients (APIs) Co-administrated with This DIG
       ICD Disease Classification 02 Benign/in-situ/malignant neoplasm Click to Show/Hide
Topotecan
 API Info
Ovarian cancer [ICD-11: 2C73]
 [1]
       ICD Disease Classification 05 Endocrine/nutritional/metabolic disease Click to Show/Hide
Glipizide
 API Info
Diabetes mellitus [ICD-11: 5A10]
 [2]
Lovastatin
 API Info
Hypertriglyceridaemia [ICD-11: 5C80]
 [3]
       ICD Disease Classification 06 Mental/behavioural/neurodevelopmental disorder Click to Show/Hide
Lamotrigine
 API Info
Bipolar disorder [ICD-11: 6A60]
 [4]
Hydroxyzine
 API Info
Anxiety disorder [ICD-11: 6B00]
 [5]
       ICD Disease Classification 11 Circulatory system disease Click to Show/Hide
Aspirin
 API Info
Myocardial infarction [ICD-11: BA41]
 [6]
Metoprolol
 API Info
Essential hypertension [ICD-11: BA00]
 [7]
Nitroglycerin
 API Info
Acute coronary syndrome [ICD-11: BA4Z]
 [8]
Candesartan cilexetil
 API Info
Essential hypertension [ICD-11: BA00]
 [9]
       ICD Disease Classification 12 Respiratory system disease Click to Show/Hide
Clarithromycin
 API Info
Pneumocystis pneumonia [ICD-11: CA40]
 [10]
       ICD Disease Classification 13 Digestive system disease Click to Show/Hide
Omeprazole
 API Info
Gastro-oesophageal reflux disease [ICD-11: DA22]
 [11]
Bisacodyl
 API Info
Irritable bowel syndrome [ICD-11: DD91]
 [12]
Lansoprazole
 API Info
Duodenal ulcer [ICD-11: DA63]
 [13]
Esomeprazole
 API Info
Duodenal ulcer [ICD-11: DA63]
 [14]
Dexlansoprazole
 API Info
Gastro-oesophageal reflux disease [ICD-11: DA22]
 [15]
       ICD Disease Classification 15 Musculoskeletal/connective-tissue disease Click to Show/Hide
Naproxen
 API Info
Rheumatoid arthritis [ICD-11: FA20]
 [16]
Diclofenac
 API Info
Knee osteoarthritis [ICD-11: FA01]
 [17]
Sulfasalazine
 API Info
Rheumatoid arthritis [ICD-11: FA20]
 [18]
       ICD Disease Classification 16 Genitourinary system disease Click to Show/Hide
Ibuprofen
 API Info
Dysmenorrhea [ICD-11: GA34]
 [19]
Tamsulosin
 API Info
Prostatic hyperplasia [ICD-11: GA90]
 [20]
Full List of Biological Targets of DIG (DBTs) Regulated by This DIG
      Primary active transporter (PAT)
            DBT Name: Multidrug resistance protein 2 (ABCC2) Click to Show/Hide
               Detailed Information DBT Info click to show the detail info of this DBT
               Experiment for Assessing the Biological Activity of the Studied DIG on This DBT
                    Biological Activity Inhibition ratio = 76 % (tested by experiment) [21]
                    Tested Species Homo sapiens (Human)
                    UniProt ID MRP2_HUMAN
            DBT Name: Multidrug resistance protein 1 (ABCB1) Click to Show/Hide
               Detailed Information DBT Info click to show the detail info of this DBT
               Experiment (1) for Assessing the Biological Activity of the Studied DIG on This DBT
                    Biological Activity Protein expression downregulation = 52.3 % (tested by experiment) [22]
                    Tested Species Homo sapiens (Human)
                    UniProt ID MDR1_HUMAN ; MDR3_HUMAN ; ABCB5_HUMAN
               Experiment (2) for Assessing the Biological Activity of the Studied DIG on This DBT
                    Biological Activity Inhibition ratio = 46 % (tested by experiment) [22]
                    Tested Species Homo sapiens (Human)
                    UniProt ID MDR1_HUMAN ; MDR3_HUMAN ; ABCB5_HUMAN
               Experiment (3) for Assessing the Biological Activity of the Studied DIG on This DBT
                    Biological Activity Inhibition ratio = 47 % (tested by experiment) [22]
                    Tested Species Homo sapiens (Human)
                    UniProt ID MDR1_HUMAN ; MDR3_HUMAN ; ABCB5_HUMAN
      Cell line (CELL)
            DBT Name: Prostate cancer LNCaP cells (LNCaP) Click to Show/Hide
               Detailed Information DBT Info click to show the detail info of this DBT
               Experiment for Assessing the Biological Activity of the Studied DIG on This DBT
                    Biological Activity IC50 > 100000 nM (tested by experiment) [23]
                    Tested Species Homo sapiens (Human)
                    Cellosaurus ID CVCL_0395
References
1 FDA label for approved topotecan from the official website of the U.S. Food and Drug Administration.
2 FDA label for approved glipizide from the official website of the U.S. Food and Drug Administration.
3 FDA label for approved lovastatin from the official website of the U.S. Food and Drug Administration.
4 FDA label for approved lamotrigine from the official website of the U.S. Food and Drug Administration.
5 FDA label for approved hydroxyzine from the official website of the U.S. Food and Drug Administration.
6 FDA label for approved aspirin from the official website of the U.S. Food and Drug Administration.
7 FDA label for approved metoprolol from the official website of the U.S. Food and Drug Administration.
8 FDA label for approved nitroglycerin from the official website of the U.S. Food and Drug Administration.
9 FDA label for approved candesartan cilexetil from the official website of the U.S. Food and Drug Administration.
10 FDA label for approved clarithromycin from the official website of the U.S. Food and Drug Administration.
11 FDA label for approved omeprazole from the official website of the U.S. Food and Drug Administration.
12 FDA label for approved bisacodyl from the official website of the U.S. Food and Drug Administration.
13 FDA label for approved lansoprazole from the official website of the U.S. Food and Drug Administration.
14 FDA label for approved esomeprazole from the official website of the U.S. Food and Drug Administration.
15 FDA label for approved dexlansoprazole from the official website of the U.S. Food and Drug Administration.
16 FDA label for approved naproxen from the official website of the U.S. Food and Drug Administration.
17 FDA label for approved diclofenac from the official website of the U.S. Food and Drug Administration.
18 FDA label for approved sulfasalazine from the official website of the U.S. Food and Drug Administration.
19 FDA label for approved ibuprofen from the official website of the U.S. Food and Drug Administration.
20 FDA label for approved tamsulosin from the official website of the U.S. Food and Drug Administration.
21 Effects of monoglycerides on rhodamine 123 accumulation, estradiol 17 beta-D-glucuronide bidirectional transport and MRP2 protein expression within Caco-2 cells. J Pharm Pharm Sci. 2008;11(3):45-62.
22 Effects of monoglycerides on P-glycoprotein: modulation of the activity and expression in Caco-2 cell monolayers. Mol Pharm. Sep-Oct 2008;5(5):863-75.
23 Lignanamides and nonalkaloidal components of Hyoscyamus niger seeds. J Nat Prod. 2002 Feb; 65(2):206-9.

If you find any error in data or bug in web service, please kindly report it to Dr. Zhang and Dr. Mou.